Evidence map›Paper›PMID 40491904›Full record

ArticleFrontiers in immunology2025

Construction of stable packaging cell lines for large-scale industrial BaEV-enveloped retroviral vector production.

Lijun Zhao, Chunting Qiu, Hanyi Chen, Zhuoying Yu, Jiaqi Fan, Qihong Ma, Sijian Zhan, Yaru Feng, Xiaorui Li, Ping Ma and 4 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lijun Zhao *Shenzhen Cell Valley Biopharmaceuticals Co., LTD, Shenzhen, China.
Chunting Qiu *Department of Infectious Diseases Tianjin Second People's Hospital, Tianjin, China.
Hanyi Chen *Shenzhen Cell Valley Biopharmaceuticals Co., LTD, Shenzhen, China.
Zhuoying Yu *School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
Jiaqi FanShenzhen Cell Valley Biopharmaceuticals Co., LTD, Shenzhen, China.
Qihong MaShenzhen Cell Valley Biopharmaceuticals Co., LTD, Shenzhen, China.
Sijian ZhanShenzhen Cell Valley Biopharmaceuticals Co., LTD, Shenzhen, China.
Yaru FengGuangdong Junhou Biopharmaceuticals Co., LTD, Zhongshan, China.
Xiaorui LiSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
Ping MaDepartment of Infectious Diseases Tianjin Second People's Hospital, Tianjin, China.
Weijia WangZhongshan City People's Hospital, Zhongshan, Guangdong, China.
Yuanyuan ShiShenzhen Cell Valley Biopharmaceuticals Co., LTD, Shenzhen, China.
Jin-Fu XuDepartment of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai, China.
Jianxun WangShenzhen Cell Valley Biopharmaceuticals Co., LTD, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Viral vectors with Baboon endogenous virus (BaEV) envelope proteins have been demonstrated to markedly increase gene transfer efficiency to NK cells. Nevertheless, the cytotoxicity of the BaEV envelope protein necessitates the production of this type of viral vector by transient transfection, which significantly constrains its potential for large-scale industrial application. Methods: In this study, we constructed a stably packed BaEV-PackRV cell line for BaEVenveloped retroviral vectors. This packaging cell line was constructed to stably express gag, pol, and BaEV envelope proteins, which are essential for retroviral packaging. To this end, we avoided the occurrence of syncytia during virus preparation by knocking out the ASCT-1/2 receptor in the packaging cell line. Results and Discussion: Compared with the existing methods, the transduction efficiency of the retroviral vector produced by BaEV-PackRV was significantly greater in primary immune cells at a lower multiplicity of infection (MOI), and the transduced CAR-T or CAR-NK cells maintained good expansion capacity and enhanced cytotoxicity. On this basis, our system enables large-scale industrial production of BaEV-coated retroviral vectors while significantly reducing costs.This will greatly improve the efficacy of NK cell gene transfer and the effectiveness of related treatments.

Indexed as

Endogenous RetrovirusesGenetic VectorsViral Envelope ProteinsVirus AssemblyAnimalsCell LineHumansKiller Cells, NaturalRetroviridaeTransduction, GeneticViral Envelope ProteinsASCT-1/2 knockoutBaEV-enveloped retrovirusCAR-NK cell therapyindustrial-large-scale productionstable packaging cell line

Identifiers

PMID40491904
PMCPMC12146362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.